商务合作
动脉网APP
可切换为仅中文
Award Will Support the First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy
该奖项将支持美国第一个自体神经治疗的多中心、多患者1/2a期临床试验
SAN DIEGO, May 15, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a California-based private biotechnology company developing personalized regenerative therapies, has received a CLIN2 grant award of $8 million from the California Institute for Regenerative Medicine (CIRM), the world's largest institution dedicated to regenerative medicine, to support clinical research aimed at treating Parkinson's disease (PD)..
圣地亚哥,2024年5月15日/新闻专线/--总部位于加利福尼亚州的私人生物技术公司Aspen Neuroscience,Inc.开发个性化再生疗法,已获得加利福尼亚再生医学研究所(CIRM)授予的800万美元的CLIN2奖助金,该研究所是世界上最大的致力于再生医学的机构,旨在支持旨在治疗帕金森病(PD)的临床研究。。
Award will support the first U.S. multi-center, multi-patient Phase 1/2a trial of an autologous neurological therapy
该奖项将支持美国第一个自体神经治疗的多中心、多患者1/2a期临床试验
The grant, a first for an autologous therapeutic for degenerative neurological conditions, will help advance the development of ANPD001, an investigational iPSC-derived dopaminergic neuron replacement therapy.
该赠款是首次用于退行性神经疾病的自体治疗,将有助于推动ANPD001的发展,ANPD001是一种研究性iPSC衍生的多巴胺能神经元替代疗法。
ANPD001 is being studied in a First in Human Phase 1/2a clinical trial for patients with moderate to advanced PD, to assess safety and tolerability. This is the first use of the autologous approach in a multi-patient and multi-center clinical trial.
ANPD001正在针对中度至晚期PD患者的首次人体1/2a期临床试验中进行研究,以评估安全性和耐受性。这是在多患者和多中心临床试验中首次使用自体方法。
'This clinical award represents a significant step forward in the treatment landscape of Parkinson's disease by advancing individualized therapy, which has the potential to restore motor function in patients impacted by this devastating condition,' said Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at CIRM. .
CIRM治疗发展副总裁Abla Creasy博士说:“这一临床奖项通过推进个体化治疗,在帕金森病治疗领域迈出了重要的一步,有可能恢复受这种破坏性疾病影响的患者的运动功能。”。
'We are honored to receive support from CIRM, an incredible sponsor of innovation. ANPD001 was developed in California, and is now being produced and studied here,' said Damien McDevitt, PhD, President and CEO of Aspen Neuroscience, Inc. 'Providing patients in this study with dopamine neurons made from their own cells is a huge leap forward for personalized medicine, and has the potential to impact the entire field of neurodegenerative disorders.'.
“我们很荣幸得到CIRM的支持,CIRM是一家令人难以置信的创新赞助商。Aspen Neuroscience,Inc.总裁兼首席执行官达米恩·麦克德维特(DamienMcDevitt)博士说,ANPD001是在加利福尼亚州开发的,现在正在这里进行生产和研究。在这项研究中,为患者提供由自身细胞制成的多巴胺神经元是个性化医学的一个巨大飞跃,有可能影响整个神经退行性疾病领域。
Affecting more than one million Americans, PD is a neurodegenerative disorder that causes walking and motor problems, as well as impaired balance and coordination. Existing therapies alleviate symptoms but do not treat the underlying disease process, leading to a significant unmet medical need for those suffering from this chronic condition..
PD是一种神经退行性疾病,影响着100多万美国人,会导致行走和运动问题,以及平衡和协调能力受损。现有的疗法可以缓解症状,但不能治疗潜在的疾病过程,导致患有这种慢性病的人的医疗需求严重未得到满足。。
'Parkinson's disease is the most common neurodegenerative movement disorder, primarily by depleting dopamine neurons in the midbrain. By the time of diagnosis, it is common for people with Parkinson's to have lost the majority of dopaminergic (DA) neurons, leading to progressive loss of motor and neurological function,' explained Edward Wirth III, MD, PhD, Chief Medical Officer of Aspen Neuroscience.
帕金森氏病是最常见的神经退行性运动障碍,主要是通过消耗中脑的多巴胺神经元。Aspen Neuroscience首席医学官、医学博士爱德华·沃思三世(EdwardWirth III)解释说,到确诊时,帕金森氏症患者通常会失去大部分多巴胺能(DA)神经元,导致运动和神经功能逐渐丧失。
'Our Phase 1/2a study has completed enrollment, the first patient has been dosed and we will continue dosing patients this year.'.
“我们的1/2a期研究已经完成登记,第一名患者已经服用,今年我们将继续给患者服用。”。
About the California Institute for Regenerative Medicine (CIRM)
关于加利福尼亚再生医学研究所(CIRM)
At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission.
在CIRM,我们永远不会忘记,我们是由加利福尼亚州人民创建的,旨在加速对未满足医疗需求的患者进行干细胞治疗,并以紧迫感行动以成功完成这项任务。
To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies.
为了应对这一挑战,我们的团队由训练有素且经验丰富的专业人员组成,在动手创业的环境中积极与学术界和工业界合作,以快速跟踪当今最有前途的干细胞技术的发展。
With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one of the world's largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality. For more information go to www.cirm.ca.gov
CIRM拥有55亿美元的资金和150多个活跃的干细胞项目,是世界上最大的机构之一,致力于帮助人们实现细胞医学的未来。有关更多信息,请访问www.cirm.ca.gov
About the ASPIRO Trial
关于ASPIRO审判
ASPIRO is an open-label Phase 1/2a clinical trial to assess the safety and tolerability of ANPD001 in patients with moderate to severe Parkinson's disease. The trial includes patients 50–70 years of age, and excludes patients with cognitive impairment and other comorbidities that could preclude treatment.
ASPIRO是一项开放标签的1/2a期临床试验,用于评估ANPD001在中重度帕金森病患者中的安全性和耐受性。该试验包括50-70岁的患者,不包括认知障碍和其他可能妨碍治疗的合并症患者。
All enrolled patients are under the care of a movement disorder specialist..
所有登记的患者都由运动障碍专家照顾。。
The primary study endpoint is safety and tolerability of two sequential escalating doses of ANPD001. Secondary endpoints include improvement in 'on' time, when patients experience periods of good symptom control, and improvements in motor symptoms and quality of life based on standard Parkinson's disease rating scales.
主要研究终点是两次连续递增剂量的ANPD001的安全性和耐受性。次要终点包括患者经历良好症状控制期时“开启”时间的改善,以及基于标准帕金森病评定量表的运动症状和生活质量的改善。
.
.
About Aspen Neuroscience
关于Aspen Neuroscience
Headquartered in San Diego, Aspen Neuroscience, Inc. is a clinical development-stage, private company focused on autologous regenerative medicine. The company's patient-derived iPSC platform is used to create personalized therapies to address diseases with high unmet medical needs, beginning with autologous neuron replacement for Parkinson's disease. .
Aspen Neuroscience,Inc.总部位于圣地亚哥,是一家临床开发阶段的私营公司,专注于自体再生医学。该公司的患者衍生iPSC平台用于创建个性化疗法,以解决医疗需求未得到满足的疾病,首先是帕金森氏病的自体神经元替代。。
Aspen combines cell biology with the latest machine learning and genomic approaches to investigate patient-specific, restorative cell treatments. The company has developed a best-in-class platform to create and optimize pluripotent-derived cell therapies, which includes in-house bioinformatics, manufacturing and quality control.
白杨 将细胞生物学与最新的机器学习和基因组方法相结合,以研究针对患者的恢复性细胞治疗。该公司开发了一个一流的平台,用于创建和优化多能衍生细胞疗法,其中包括内部生物信息学,制造和质量控制。
For more information and important updates, please visit https://www.aspenneuroscience.com..
有关更多信息和重要更新,请访问 https://www.aspenneuroscience.com..
View original content to download multimedia:https://www.prnewswire.com/news-releases/aspen-neuroscience-receives-clin2-grant-for-anpd001-from-california-institute-for-regenerative-medicine-cirm-302145692.html
查看原始内容以下载多媒体:https://www.prnewswire.com/news-releases/aspen-neuroscience-receives-clin2-grant-for-anpd001-from-california-institute-for-regenerative-medicine-cirm-302145692.html
SOURCE Aspen Neuroscience, Inc.
来源Aspen Neuroscience,Inc。